1. Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee F-C, Kallender H, Cecchi F, Rabe DC (2013) Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 8:e54014
2. McDonnell C, Hill A, McNamara D, Walsh T, Bouchier-Hayes D (2000) REVIEWS—Tumour micrometastases: the influence of angiogenesis. Eur J Surg Oncol 26:105–115
3. Steri V, Ellison TS, Gontarczyk AM, Weilbaecher K, Schneider JG, Edwards D, Fruttiger M, Hodivala-Dilke KM, Robinson SD (2014) Acute depletion of endothelial β3-integrin transiently inhibits tumor growth and angiogenesis in mice. Circ Res 114:79–91
4. Deng YH, Xu D, Su YX, Cheng YJ, Yang YL, Wang XY, Zhang J, You QD, Sun LP (2015) Synthesis and biological evaluation of novel oxazolo [5, 4‐d] pyrimidines as potent VEGFR‐2 inhibitors. Chem Biodivers 12:528–537
5. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55:3964–3968